Zeeland

Researchers are evaluating the effectiveness of the MiLES intervention, a web-based program designed for employers, to improve the successful return to work (RTW) of employees diagnosed with cancer within the past two years. This randomized controlled trial also aims to assess the cost-effectiveness and return on investment of the MiLES intervention compared to usual care. The study includes 140 employer-employee dyads, focusing on both the employee's and employer's outcomes related to RTW and quality of life. Employers in the intervention group will have unlimited access to the MiLES website, which offers interactive videos, conversation checklists, tips, information about RTW guidance, involved stakeholders, and relevant legislation. These resources intend to support employers in effectively communicating with and assisting their employees with cancer during sick leave and return to work. The control group will receive care as usual without access to the MiLES intervention. Participants will complete questionnaires at the start of the study and at 3, 6, and 12 months after enrollment to assess outcomes such as successful RTW, quality of life, work-related support, and satisfaction with support. Employers will report on their self-efficacy in providing RTW support and satisfaction with the RTW process. The follow-up period lasts 12 months, and a process evaluation based on the UK Medical Research Council framework will also be conducted.